Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system-focused drug discovery, announced recently that it had entered into an agreement with Dorian Therapeutics to provide access to one of its novel small molecule libraries specifically designed to target deubiquitylase (DUB) enzymes
Cyclica, a leading biotechnology company that commercialized Ligand Express announced its novel, first-in-class drug design technology, Ligand DesignTM on stage at the Collision Conference in Toronto
Researchers at the University of Georgia have discovered two new drug targets to treat Acute Respiratory Distress Syndrome, or ARDS, a life-threatening lung condition that makes breathing difficult or impossible
Synlogic, Inc., a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, recently announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Biotic medicine, SYNB1891, a dual innate immune activator engineered to express a STING agonist, in combination with Roche’s PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab (Tecentriq®) in patients with advanced solid tumors
Avadel Pharmaceuticals plc (Nasdaq: AVDL), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the Company’s fourth Hospital Product, AV001
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to begin a Phase 1/2 clinical trial evaluating its novel, one-time gene therapy ABO-202 for the treatment of CLN1 disease, following acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA).
When developing new pharmaceutical products, it is very important to get to the Phase I clinical trial in a fast, efficient and cost-effective way.
Formulation challenges for enhancing the bioavailability of poorly soluble API’s can be solved by spray drying.
Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into an exclusive licensing agreement with Fundación MEDINA, the not-for-profit Spanish foundation Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia
Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and ZoBio, the leading contract research organization in integrated fragment-based drug discovery, recently announced significant progress made as part of their collaboration to identify therapeutic lead candidates for Gotham’s initial portfolio of epitranscriptomic targets
|
|
|
|
|
|
|
|
|